An observational study in Coronary Artery Disease, sponsored by HeartFlow, Inc.. Completed at 15 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by HeartFlow, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Coronary Artery Disease by HeartFlow, Inc. — 4 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · HeartFlow, Inc..
Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., this one is the only one that started in 2013, is one of 7 observational ones, and was the 3rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →4 of the 12 studies in Coronary Artery Disease by HeartFlow, Inc. are open now, in 1 country. Recruiting first, the newest first:
HeartFlow, Inc. · Sites in United States
Ages 18+
HeartFlow, Inc. · Sites in United States
Healthy volunteers
HeartFlow, Inc. · Sites in United States
Ages 40–79
HeartFlow, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2013.
This study's enrollment of 584 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 350 across the 5 interventional studies, 584 across the 7 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
HeartFlow, Inc. is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
2 of the studies in Coronary Artery Disease by HeartFlow, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831409HeartFlow, Inc.Using CTA Measures to Define Cardiac Risk In NFL Alumni | 2026-12-31 |
| NCT07834372HeartFlow, Inc.REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the PLATFORM Study is to compare clinical outcomes, resource utilization, and quality of life (QOL) of FFRCT-guided evaluation versus standard practice evaluation in patients with suspected CAD in order to further inform patients, health care providers, and other stakeholders about which technologies are most effective and efficient in the diagnosis of CAD
The OVERALL OBJECTVE of this post-market, multicenter, longitudinal, prospective, consecutive cohort study is to compare clinical outcomes, resource utilization, and quality of life (QOL) in subjects receiving standard practice evaluation and treatment versus subjects receiving FFRCT-guided evaluation and treatment in subjects with suspected CAD in order to further inform patients, health care providers, and other stakeholders about which technologies are most effective and efficient in the diagnosis of CAD. Cohort 1 of this study will assess outcomes incorporating standard practice evaluation and Cohort 2 will assess outcomes incorporating FFRCT-guided evaluation. Each Cohort will be further delineated based upon initial presentation, whereas subjects presenting for initial non-invasive testing will be designated as Cohorts 1A and 2A; and subjects already referred for ICA will be designated as Cohorts 1B and 2B.
SPECIFIC OBJECTIVES for sequential cohort comparisons:
Subjects referred with intermediate likelihood of obstructive CAD with an Updated Diamond-Forrester (UDF) risk score 20-80% with symptomatic, suspected CAD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
Number of Participants With Negative Invasive Coronary Angiography
The primary endpoint of the PLATFORM Study is 90 day (+30/-15 days) rate of coronary angiogram showing no stenosis \> 50% in a vessel \> 2.0 mm by Quantitative Coronary Angiography (QCA), or no invasively-measured FFR \< 0.80 in a segment distal to a stenosis in a vessel \> 2.0 mm by QCA between Cohort 1 and 2.
Time frame: 90 Days from first test
Number of MACE
90 days (+30/-30 days) Cohort 1 and Cohort 2 Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. Non-fatal MI 3. Unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization
Time frame: 90 days from first test
Number of MACE or Vascular Complications
90 days (+30/-30 days) Major Adverse Coronary Event (MACE) rates, defined as: all cause death, non-fatal MI, unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization and vascular complications (related to any coronary testing or procedure).This secondary endpoint compared the rates of MACE and vascular events across all subjects in Cohort 1 vs Cohort 2, Cohort 1A vs Cohort 2A and Cohort 1B vs Cohort 2B. The rates of MACE and vascular events were calculated by dividing the number of subjects with MACE and vascular events by the total number of subjects assigned to each analysis population.
Time frame: 90 days from first test
Number of Participants With Resource (CV Test Types Performed) Utilization at 90 Days
Comparison of Resource utilization between cohort 1 and cohort 2 at 90 days (+/- 30 days): 1. Non-invasive diagnostic tests 2. Invasive diagnostic tests 3. Coronary revascularization procedures
Time frame: 90 days from first test
Number of Participants With Medications Used by Type
Comparison of medication use between cohort 1A, 1B and cohort 2A, 2B at 90 days (+/- 15 days)
Time frame: at 90 days
Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice.
| Milestone | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT |
|---|---|---|---|---|
| Started | 100 | 104 | 187 | 193 |
| Completed | 100 | 104 | 187 | 193 |
| Not completed | 0 | 0 | 0 | 0 |
The primary endpoint of the PLATFORM Study is 90 day (+30/-15 days) rate of coronary angiogram showing no stenosis \> 50% in a vessel \> 2.0 mm by Quantitative Coronary Angiography (QCA), or no invasively-measured FFR \< 0.80 in a segment distal to a stenosis in a vessel \> 2.0 mm by QCA between Cohort 1 and 2.
| Participants | Planned Invasive Test Usual Care Strategy (Cohort 1B) | Planned Invasive Test FFRCT Guided Strategy (Cohort 2B) |
|---|---|---|
| Number of Participants With Negative Invasive Coronary Angiography | 137 | 24 |
90 days (+30/-30 days) Cohort 1 and Cohort 2 Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. Non-fatal MI 3. Unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization
| Participants | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT |
|---|---|---|---|---|
| Number of MACE | 1 | 0 | 2 | 2 |
90 days (+30/-30 days) Major Adverse Coronary Event (MACE) rates, defined as: all cause death, non-fatal MI, unplanned hospitalization for acute coronary syndrome (ACS) leading to urgent revascularization and vascular complications (related to any coronary testing or procedure).This secondary endpoint compared the rates of MACE and vascular events across all subjects in Cohort 1 vs Cohort 2, Cohort 1A vs Cohort 2A and Cohort 1B vs Cohort 2B. The rates of MACE and vascular events were calculated by dividing the number of subjects with MACE and vascular events by the total number of subjects assigned to each analysis population.
| Participants | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT |
|---|---|---|---|---|
| Number of MACE or Vascular Complications | 0 | 1 | 2 | 7 |
Comparison of Resource utilization between cohort 1 and cohort 2 at 90 days (+/- 30 days): 1. Non-invasive diagnostic tests 2. Invasive diagnostic tests 3. Coronary revascularization procedures
| Participants | Non-invasive (Cohort 1A) Usual Care | Non-invasive Cohort (Cohort 2A) FFRCT | Invasive Cohort (Cohort 1B) Usual Care | Invasive Cohort (Cohort 2B) FFRCT |
|---|---|---|---|---|
| ECG | 2 | 3 | 59 | 32 |
| Stress Echo | 2 | 0 | 7 | 6 |
| Nuclear/Stress MPI/CMR | 3 | 2 | 23 | 5 |
| cCTA without FFRCT | 8 | 2 | 21 | 12 |
| cCTA with FFRCT | 0 | 17 | 0 | 64 |
| IVUS, OCT, or FFR | 3 | 7 | 17 | 30 |
| ICA | 12 | 19 | 187 | 76 |
| PCI | 3 | 9 | 42 | 45 |
| CABG | 2 | 1 | 17 | 10 |
Comparison of medication use between cohort 1A, 1B and cohort 2A, 2B at 90 days (+/- 15 days)
| participants (total count) | Non-invasive (Cohort 1A) Usual Care | Non-invasive Cohort (Cohort 2A) FFRCT | Invasive Cohort (Cohort 1B) Usual Care | Invasive Cohort (Cohort 2B) FFRCT |
|---|---|---|---|---|
| Aspirin | 29 | 45 | 115 | 90 |
| Statin | 24 | 29 | 83 | 77 |
Collected over Clinical Outcomes at 1 Year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-invasive (Cohort 2) Usual Care | 0/100 (0%) | 2/100 (2%) | 6/100 (6%) |
| Non-invasive Cohort (Cohort 2) FFRCT | 0/104 (0%) | 1/104 (1%) | 13/104 (12.5%) |
| Invasive Cohort (Cohort 1) Usual Care | 1/187 (0.5%) | 6/187 (3.2%) | 137/187 (73.3%) |
| Invasive Cohort (Cohort 1) FFRCT | 0/193 (0%) | 9/193 (4.7%) | 24/193 (12.4%) |
| Event | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT |
|---|---|---|---|---|
| MACE or vascular complicationsCardiac disorders | 1/100 | 1/104 | 4/187 | 7/193 |
| Nonfatal MICardiac disorders | 1/100 | 0/104 | 1/187 | 1/193 |
| All-cause deathCardiac disorders | 0/100 | 0/104 | 1/187 | 0/193 |
| Hospitalization with urgent revascularizationCardiac disorders | 0/100 | 0/104 | 0/187 | 1/193 |
| Event | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT |
|---|---|---|---|---|
| Invasive catheterization without obstructive CADCardiac disorders | 6/100 | 13/104 | 137/187 | 24/193 |
| Age, Continuous(years) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Mean | 63.36 ± 10.93 | 60.72 ± 10.20 | 57.91 ± 10.72 | 59.48 ± 9.33 | 60.86 ± 10.54 |
| Sex: Female, Male(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Female | 79 | 74 | 34 | 44 | 231 |
| Male | 108 | 119 | 66 | 60 | 353 |
| Diabetes(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Count of participants | 36 | 30 | 8 | 6 | 80 |
| Current smoker(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Count of participants | 42 | 38 | 22 | 23 | 125 |
| Hypertension(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Count of participants | 111 | 111 | 38 | 57 | 317 |
| Hyperlipidemia(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Count of participants | 76 | 77 | 22 | 28 | 203 |
| Atypical angina(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Count of participants | 122 | 142 | 91 | 80 | 435 |
| Prior noninvasive testing(Participants) | Invasive Cohort (Cohort 1) Usual Care | Invasive Cohort (Cohort 1) FFRCT | Non-invasive (Cohort 2) Usual Care | Non-invasive Cohort (Cohort 2) FFRCT | Total |
|---|---|---|---|---|---|
| Count of participants | 92 | 100 | 0 | 5 | 197 |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2025, 9 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HeartFlow, Inc.